新型脂质疗法在一名患有动脉粥样硬化疾病的难治性杂合子家族性高胆固醇血症患者中的应用。
Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease.
作者信息
Weintraub Spencer F, Schillow Jessica A, Azari Bani M, Hirsh Benjamin J
机构信息
Zucker School of Medicine at Hofstra/Northwell, Department of Medicine, Northwell Health, Hempstead, New York, USA.
North Shore University Hospital, Northwell Health, Manhasset, New York, USA.
出版信息
JACC Case Rep. 2022 Oct 19;4(20):1327-1330. doi: 10.1016/j.jaccas.2022.06.021.
Compound heterozygous familial hypercholesterolemia patients are phenotypically similar to homozygous familial hypercholesterolemia patients, present with significant elevations of low-density lipoprotein cholesterol, and are at risk of cardiovascular disease. Although new treatment options are emerging, the stepwise approach to the use of different therapies has not been well described. ().
复合杂合子家族性高胆固醇血症患者在表型上与纯合子家族性高胆固醇血症患者相似，表现为低密度脂蛋白胆固醇显著升高，并有患心血管疾病的风险。尽管新的治疗选择不断涌现，但不同疗法的逐步应用方法尚未得到充分描述。（）
Zotero 插件